| アブストラクト | Poly (ADP-Ribose) polymerase inhibitors (PARPi) have emerged as a targeted therapy in cancer treatment with promising results in various types of cancer. This work aims to investigate the profile of adverse drug reactions (ADRs) associated with PARPi through the reports provided by the Eudravigilance (EV) database. We also intend to analyze the potential association of peripheral neuropathy to PARPi. Data on individual case safety reports (ICSRs) were obtained by accessing the European spontaneous reporting system via the EV website. A total of 12,762 ICSRs were collected from the EV database. Serious cases of nervous system disorders were analyzed providing strong evidence that peripheral neuropathy was reported in a higher frequency in patients treated with niraparib. Most cases reported a not recovered/not resolved outcome and involved drug withdrawal. However, several studies suggest that PARPi attenuate chemotherapy-induced painful neuropathy. Unexpected ADRs such as peripheral neuropathy may also occur, mostly in patients taking niraparib. Further pharmacovigilance studies should be conducted in this area to clarify with more precision the toxicity profile of these drugs. |
|---|
| ジャーナル名 | Current oncology (Toronto, Ont.) |
|---|
| Pubmed追加日 | 2023/7/28 |
|---|
| 投稿者 | Jesus, Mafalda; Cabral, Antonio; Monteiro, Cristina; Duarte, Ana Paula; Morgado, Manuel |
|---|
| 組織名 | Health Sciences Faculty, University of Beira Interior (FCS-UBI), 6200-506;Covilha, Portugal.;Health Sciences Research Center, University of Beira Interior (CICS-UBI),;6200-506 Covilha, Portugal.;Pharmaceutical Services of Local Healthcare Unit of Guarda, 6300-749 Guarda,;Portugal.;UFBI-Pharmacovigilance Unit of Beira Interior, University of Beira Interior,;Pharmaceutical Services of University Hospital Center of Cova da Beira, 6200-251 |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37504339/ |
|---|
